Search Tufts Medicine

While much has been learned about the acute phase of Coronavirus disease 2019 (COVID-19) in the last year, little is known about the recovery phase. There have recently been several reports in the news and in the medical literature about a prolonged recovery phase after developing acute COVID-19 in some individuals who may have persistent symptoms many months after infection, developing the so called “long COVID”.

REACT-AF is a multicenter, prospective, randomized clinical trial comparing two treatment strategies for stroke prevention in patients with a history of paroxsymal or persistent atrial fibrillation and moderate stroke-risk.

This study is being conducted in healthy children from age 6 months to age 12 years. The study is looking at how well the Moderna mRNA vaccine works when given to healthy children for the prevention of COVID-19.

This study is to evaluate Safety & Tolerability of multiple doses of an experimental i.v. medication (called AP-SA02) in Phase 1b and to evaluate Efficacy, Safety & Tolerability of multiple doses of the same experimental medication in Phase 2a, as compared to Placebo in patients with certain bacterial infection (bacteria named Staphylococcus aureus) of your blood stream. The experimental drug or Placebo will be given in addition to any treatment given for the Blood stream infection by Staphylococcus aureus.

This is a Phase 3, open-label, follow-up study to evaluate the long-term safety and efficacy of sotatercept when added to background PAH therapy for the treatment of PAH. Participants eligible to enroll in the study will have participated in and completed the relevant study requirements of the PAH sotatercept clinical studies. Participants who have discontinued from a previous PAH sotatercept clinical study will not be eligible to enroll in this LTFU study.

Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, symptomatic AS. The primary objective is to demonstrate the safety and effectiveness of the Medtronic TAVR system (on the background of GDMT) is superior to GDMT alone.

The primary objective is to evaluate the efficacy of levosimendan TNX-103 compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance from Day 1 to Week 12. This is a multicenter, parallel, double-blind study in subjects with PH-HFpEF and will be screened for a 1:1 ratio to receive an oral dose of 2 mg/day levosimendan or placebo for Weeks 1 to 4 and 3 mg/day for Weeks 5 to 12.

This is a randomized, phase 2, double-blind, placebo-controlled study of KER-012 in combination with background therapy in participants with PAH of World Health Organization (WHO) Group 1, functional class II-III. Participants will be randomly assigned in a 2:2:2:3 ratio to receive KER-012 (Dose A), KER-012 (Dose B), KER-012 (Dose C), or placebo by subcutaneous injection (SC) every 4 weeks for a period of 24 weeks in the placebo-controlled treatment period of the study while on background therapy.

A prospective, multi-center, 2:1 randomized (AGENT to POBA), controlled, single-blind, superiority trial. Up to 40 sites in the United States, at least 480 subjects will be enrolled in the trial. An interim analysis will be performed prior to the end of the initial enrollment of 480 patients. The final sample size may be increased up to a maximum of 600 subjects enrolled in the trial.

This clinical investigation is intended to evaluate the safety and effectiveness of Abbott’s Amplatzer^TM Amulet^TM Left Atrial Appendage (LAA) occluder device (“Amulet device”) compared to commercially available non-vitamin K antagonist oral anticoagulant (NOAC) drugs in patients with non-valvular atrial fibrillation (AF) who are at increased risk for ischemic stroke and who are tolerant of long-term NOAC therapy.

This study aims to learn more about the investigational drug, ASTX727, and another drug, venetoclax, when given in combination. It also aims to evaluate potential pharmocokinetics (PK) interactions for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

The primary purpose of the study is to rule out drug-drug interactions between ASTX727 and venetoclax combination therapy.